Tenoretic

Quick links to important sections

Tenoretic

Selected form

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Tenoretic

Tenoretic is a prescription-only, fixed-dose combination product specifically classified as a Beta-Blocker and Diuretic Combination medicine. This drug entity is formulated as an oral tablet used for the long-term management of high blood pressure, or hypertension, in adults.

Property Description
Active Ingredients Atenolol, Chlorthalidone
Form Oral tablet
Pharmacological Class Beta-Blocker and Diuretic Combination
Common Use Hypertension (High Blood Pressure)
Origin Synthetic

Composition and Form: A Dual-Action Formulation

Tenoretic is composed of two synthetic active ingredients: atenolol and chlorthalidone. Atenolol is a selective beta1-adrenergic receptor antagonist, commonly known as a cardioselective beta-blocker, and chlorthalidone is a sulfonamide-derived agent belonging to the class of thiazide-like diuretics. This specific dual-action formulation is clinically recognized for providing greater blood pressure reduction than either agent used as a single therapy. The tablet form ensures convenient oral administration and accurate delivery of both agents simultaneously.


General Purpose: Controlling Chronic Hypertension

The general purpose of Tenoretic is to achieve a sustained reduction in the pressure exerted on arterial walls, thereby controlling chronic hypertension. It accomplishes this by combining the effects of heart rate regulation and fluid and salt reduction within the body. Fixed-dose combinations of beta-blockers and diuretics simplify treatment regimens for hypertension, which can improve long-term adherence to therapy. The combination is utilized when a single agent is unable to effectively reach target blood pressure levels, offering a powerful synergistic effect against the root causes of high blood pressure.

What side effects are possible with Tenoretic?

Possible Side Effects and Safety Information

The official safety profile for the fixed-dose combination of atenolol and chlorthalidone details potential adverse reactions categorized by frequency and the body system affected. Common effects, as classified in regulatory documents, include fatigue, bradycardia (slow heart rate), cold extremities, and gastrointestinal disturbances.


System-Organ Classes and Serious Reactions

Adverse reactions are documented across several system-organ classes, including Cardiac Disorders, Vascular Disorders, Nervous System Disorders, and Metabolism and Nutrition Disorders. The regulatory labels identify rare but clinically significant adverse reactions, such as the deterioration or precipitation of Heart Failure, bronchospasm (severe breathing difficulty), and severe shifts in metabolic balance, like hypokalemia (low potassium) associated with the diuretic component.

Serious restrictions on use exist, and the medicine is contraindicated in individuals with conditions such as second- or third-degree heart block, cardiogenic shock, or anuria (absence of urine output).


Safety Patterns and Special Populations

Certain safety patterns are tied to the course of treatment. Effects like fatigue may be more noticeable at the start of treatment, while the risk of electrolyte disturbances is associated with long-term use. Specific safety considerations are documented for certain populations: the beta-blocker component may mask the symptoms of hypoglycemia in patients with diabetes mellitus, and regulatory caution is required for individuals with renal impairment due to altered drug clearance. Furthermore, the official labeling warns that abrupt cessation, particularly in patients with existing heart conditions, may result in the exacerbation of angina pectoris.

Overdose and Emergency Response

Overdose and when to seek help

Regulatory documents define the Tenoretic overdose profile by the severe manifestations resulting from its two components: the cardiotoxicity of atenolol and the fluid/electrolyte disturbance from chlorthalidone.

Overdose may be manifested by severe bradycardia (slow heart rate), profound hypotension (low blood pressure), acute congestive heart failure, bronchospasm, and severe fluid and electrolyte disturbances (Source: FDA prescribing information). Documented signs include lethargy, seizures, and systemic indicators of electrolyte collapse, such as muscle cramps and wrinkled skin.

Immediate Actions and Management

Due to the potential for life-threatening or very serious effects, the regulatory instruction is to Get emergency help right away if overdose is suspected or if symptoms such as fainting, very slow heartbeat, or trouble breathing occur. Contact a poison control center or emergency room at once.

No specific antidote is known for the combination product. Management is directed to symptomatic and supportive treatment to address the acute clinical signs. Procedural steps may include removal of unabsorbed drug via activated charcoal or gastric lavage. The atenolol component is documented as being removable by hemodialysis (Source: NIH DailyMed).

Therapeutic Uses of Tenoretic

Tenoretic is a fixed-dose combination product that is primarily indicated for the treatment of hypertension (high blood pressure). Its therapeutic scope centers on the long-term management of Primary (Essential) Hypertension. The medication is commonly used to help with conditions presenting with systemic or localized discomfort and is applied across domains where additional symptomatic support is needed.

Therapeutic Scope

Its use plays a role in managing sustained control of the chronic hemodynamic load—the persistently elevated arterial pressure that is often asymptomatic. It is generally prescribed when a patient’s high blood pressure cannot be adequately managed by a single antihypertensive agent, and may be part of symptomatic management when a combined strategy is appropriate. This use supports the patient during difficult episodes by easing distress and may contribute to reducing the overall systemic burden.

“The use may assist with maintaining a sense of stability when symptoms are more noticeable, supporting general well-being during symptomatic phases.”

The medication is relevant in conditions characterized by periods of heightened physiological stress and is used across domains where additional symptomatic support is needed. It is relevant for managing symptoms that interfere with daily comfort and may assist with managing more challenging or severe hypertension.

Quick Fact: Management of Asymptomatic Hemodynamic Load
The fixed-dose combination supports achieving and maintaining blood pressure control, which helps manage symptoms related to systemic imbalance.

Eligibility and Restrictions for Use

Tenoretic's eligibility is determined by strict regulatory guidelines, limiting its use primarily to Adults managing hypertension. The medicine is contraindicated in a number of patients due to the combined action of its ingredients. Absolute prohibitions include severe cardiovascular conditions such as cardiogenic shock, uncontrolled cardiac failure, second- or third-degree A-V block, sinus bradycardia, and sick sinus syndrome. Contraindications also extend to specific metabolic and renal states, including anuria, severe renal failure, metabolic acidosis, and refractory hypokalemia. Patients with a known hypersensitivity to atenolol, chlorthalidone, or sulfonamide-derived drugs must not use the medicine.

Age and Reproductive Status

The drug is not recommended for the pediatric population (children and adolescents) as its safety and effectiveness have not been established. For older adults, dosage requirements may be lower. Use is contraindicated during both pregnancy and lactation.

Conditional Use

Conditional caution is required for populations with impaired renal or hepatic function, bronchospastic disease (e.g., asthma), or diabetes mellitus, where use is restricted and subject to specific regulatory warnings.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Officially documented interactions for Tenoretic (Atenolol/Chlorthalidone) span multiple medicinal product categories. These include Antihypertensives (e.g., Calcium Channel Blockers like Verapamil), Antiarrhythmic Agents, Agents Affecting Electrolyte Balance (such as Lithium and Digitalis Glycosides), and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

Documented Interaction Mechanisms

Interactions are categorized by regulatory documents based on two primary mechanisms: Pharmacodynamic Additive Effects and altered clearance or absorption. Additive effects can increase the risk of bradycardia and heart block (e.g., with Calcium Channel Blockers) or, conversely, result in attenuation of the antihypertensive effect (e.g., with NSAIDs). The chlorthalidone component may reduce the renal clearance of co-administered drugs like Lithium, officially leading to increased serum concentrations.

Interaction-Related Restrictions and Timing Rules

Specific timing-based administration requirements are documented. The co-administration of Aluminum Hydroxide requires separation of administration by at least two hours to prevent reduced absorption of the Atenolol component. A procedural constraint exists for Clonidine, which must be gradually discontinued only after the beta-blocker component has been withdrawn for several days to avoid a hypertensive rebound phenomenon. Additionally, the label notes that the risk of cumulative effects is present in patients with Impaired Renal Function due to the renal excretion of both components.

Mechanism of Action

The combined mechanism involves two distinct agents: a selective beta1-adrenergic receptor antagonist and a thiazide-like diuretic.

Atenolol acts as a selective antagonist by binding to beta1-adrenergic receptors, primarily located in the myocardium. This blockade prevents the binding of endogenous catecholamines (e.g., norepinephrine). Mechanistically, this action decreases the spontaneous firing rate of the sinoatrial node, subsequently reducing heart rate (negative chronotropy). Concurrently, it reduces the force of myocardial contraction (negative inotropy) and decreases renin release from the juxtaglomerular cells.

Chlorthalidone is a thiazide-like diuretic that exerts its effect within the distal convoluted tubules of the kidney. It works by inhibiting the sodium-chloride cotransporter (Na^+/Cl^- cotransporter). This inhibition decreases the reabsorption of sodium and chloride ions, promoting an increased flow of ions and water into the tubular lumen (diuresis). This process facilitates the excretion of water and subsequent reduction of plasma volume.

The synergistic effect of these two components leads to a net reduction in peripheral vascular resistance and circulating fluid volume.

Dosage and Administration Information

How Tenoretic is Used

Tenoretic is administered as a fixed-dose oral tablet and is intended for the long-term management of chronic hypertension. The combination product is not indicated for the initial treatment of high blood pressure; its use is reserved for maintenance therapy or as a substitution for the individual components after successful titration.


Standard Administration and Dosing Schedule

The medicine is taken once daily and can be administered with or without food. Standard adult therapy involves two fixed strengths: 50 mg atenolol / 25 mg chlorthalidone and 100 mg atenolol / 25 mg chlorthalidone. Treatment typically initiates with the lower 50 mg/25 mg strength, with the dosage potentially increasing to the 100 mg/25 mg strength if necessary. However, increasing the atenolol component beyond 100 mg daily is not generally associated with greater antihypertensive effects.


Procedural Constraints and Special Populations

Administration requires specific procedural adjustments for certain populations. For patients with renal impairment, the dosage must be reduced according to the degree of kidney function, with maximum daily doses restricted when creatinine clearance (CrCl) falls below 35 mL/min/1.73 m^2. Dose requirements are also often lower for older adults. Use in the pediatric population (under 18 years) is not recommended as efficacy and safety have not been established. Should therapy need to be discontinued, the dosage must be withdrawn gradually over a period of approximately two weeks, which is a required procedural step for beta-blocker-containing products.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Tenoretic


Evidence for Use in Managing Primary (Essential) Hypertension

Research was studied for its role in managing chronic Primary (Essential) Hypertension. These investigations included Randomized Controlled Trials (RCTs) and controlled clinical trials. These studies examined outcomes related to systemic or functional imbalance, primarily focusing on the measured changes in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) in adults whose hypertension requires a combined strategy.

The trials monitored blood pressure readings over defined time intervals. Findings describe patterns observed in the studies where measured blood pressure levels changed during the period of observation. Evidence generally contributes to understanding physiological strain or stress associated with blood pressure management under the specific conditions of the research settings.


Comparing the Combination to Single-Agent Therapy

Several studies explored the difference between taking the fixed-dose combination and taking only one of the components (atenolol alone or chlorthalidone alone). These comparison trials was used in research exploring how symptoms change over time to see if the two agents together produced a distinct pattern of change compared to the individual agents.

The research highlighted changes measured during the study period for blood pressure, and also described patterns related to changes in heart rate—an outcome monitoring physiological strain or stress—which was observed in some studies. Data describe patterns related to the measured blood pressure changes achieved with the combination versus the monotherapies.


Evaluating Long-Term Outcomes and Durability

Research has also examined the potential for sustained results over time, particularly concerning long-term outcomes related to systemic or functional imbalance such as stroke and heart attack. The assessment of these long-term outcomes is often informed by clinical trials and meta-analyses conducted on the drug classes—beta-blockers and thiazide-like diuretics—rather than trials specifically dedicated to the fixed-dose Tenoretic combination itself. Consequently, long-term effects are not fully established based solely on combination-specific trials.

Key Studies & References

  1. Atenolol and chlorthalidone therapy for hypertension: a double-blind comparison (Curry et al.)

Frequently Asked Questions (FAQ)

Common questions about Tenoretic (FAQ)


Q: How quickly does Tenoretic start working to lower blood pressure?

A: Studies indicate that the atenolol component, which helps slow the heart rate, usually shows a significant effect within one hour after you take a dose. The maximum effect is generally observed around two to four hours after administration.

Q: What is the full therapeutic effect time for Tenoretic?

A: The effects of a single dose, particularly the beta-blocking and blood pressure-lowering properties, are generally designed to persist for at least 24 hours. Achieving the maximum, stable reduction in long-term blood pressure requires taking the medication consistently as part of chronic therapy.

Q: Can Tenoretic cause weight gain or weight loss?

A: Official information reports that weight gain is a known side effect associated with the atenolol component, which is a type of beta-blocker. This weight change, often a few pounds, is typically observed within the first few months of treatment.

Q: Does Tenoretic affect sexual performance or desire?

A: Regulatory documents report that side effects can include impotence and decreased interest in sexual intercourse or loss of sexual ability, drive, or performance.

Q: Can Tenoretic cause an increase in uric acid or trigger gout?

A: The chlorthalidone component, which is a diuretic, can cause metabolic changes leading to hyperuricemia (increased uric acid levels). This elevation in uric acid is a factor that may increase the risk of a gout flare-up.

Q: What happens if I miss a dose of Tenoretic?

A: Official patient information often describes a common procedure: to take it as soon as you remember unless it is nearly time for the next scheduled dose, in which case the missed dose should be skipped. Regulatory warnings typically advise against taking a double dose to compensate for the missed one.

Q: What kind of regular monitoring or blood tests are needed while taking Tenoretic?

A: Because the diuretic component can affect the body's balance of salts and minerals (electrolytes), such as potassium, and can also impact blood sugar levels, these effects may be monitored through regular blood tests, a procedural decision made by a healthcare provider.

Q: Can Tenoretic cause depression or mood changes?

A: Official safety data lists adverse reactions related to the central nervous system, including depression and feelings of discouragement. Other related effects like drowsiness and lethargy are also reported.

Q: What is the risk of low blood pressure (hypotension) with Tenoretic?

A: Tenoretic is intended to lower blood pressure, but there is a risk it may cause the pressure to drop excessively, resulting in hypotension (low blood pressure). Warnings describe that if a person experiences faintness or dizziness, lying down until the feeling passes may be advisable.

Q: Can Tenoretic be used to treat conditions other than high blood pressure?

A: Regulatory documents state that Tenoretic is indicated specifically for the treatment of hypertension (high blood pressure). Any other uses would be based on the individual components, and not the fixed-dose combination itself.

Q: Is it safe to drink alcohol while taking Tenoretic?

A: Authoritative sources describe that limiting or avoiding alcohol may be necessary. Alcohol consumption can increase the risk of orthostatic hypotension, which is a significant drop in blood pressure that occurs when a person changes position (e.g., standing up).

Q: Can Tenoretic cause issues with vision or dry eyes?

A: The atenolol component of the medicine has been associated with various visual side effects, including reports of disturbed color perception, double vision, and loss of vision. Dry mouth is also a reported adverse effect.

Q: Does Tenoretic cause an increase in cholesterol levels?

A: Official drug facts indicate that the chlorthalidone component is associated with potential increases in both cholesterol and triglyceride levels. The decision to check these lab values during treatment is made by a healthcare provider.

Q: Are there any dietary restrictions or monitoring needed for grapefruit products while on Tenoretic?

A: While grapefruit is not commonly cited, some regulatory-related information suggests that certain juices, such as apple juice or orange juice, might prevent the full absorption of the atenolol component. Because of this, avoiding concurrent consumption of these juices and the medication may be considered.

Q: What are the signs of a serious allergic reaction to Tenoretic?

A: Signs that indicate a severe allergic reaction and require immediate medical attention include conditions such as hives, significant difficulty breathing, or swelling of the face, lips, tongue, or throat. These are listed in patient information warnings.

Q: Can Tenoretic affect my ability to drive or operate machinery?

A: Because common side effects include dizziness and fatigue, regulatory warnings state that these effects may impair a person's ability to safely drive or operate heavy machinery. Regulatory guidance suggests caution until a person understands the medication's full effect on their body.

Q: How is the use of Tenoretic affected by surgery or anesthesia?

A: Official warnings state that chronically administered beta-blocking therapy should not be routinely stopped before major surgery. However, it is important that the healthcare team, including the doctor and anesthesiologist, is informed, as careful management is needed when administering general anesthesia.

Q: Can Tenoretic cause changes in kidney lab values like creatinine?

A: The body clears the atenolol component through the kidneys, and the clearance is dependent on the glomerular filtration rate (GFR). Therefore, if kidney function is significantly impaired (creatinine clearance falls too low), the drug may accumulate, necessitating careful monitoring.

Q: Is it normal to feel more tired or dizzy when starting Tenoretic?

A: Official labeling notes that fatigue is a common adverse effect, which may be more noticeable when you first start taking the medication. Dizziness or lightheadedness, often due to blood pressure reduction, is also a frequently reported symptom in patient safety data.

Q: What are the symptoms of an electrolyte imbalance related to Tenoretic use?

A: The chlorthalidone component can cause a critical shift in metabolic balance, such as hypokalemia (low potassium). Symptoms requiring attention can include muscle cramping, confusion, extreme thirst, or weakness.

Q: Is Tenoretic the same as Tenormin or Thalitone?

A: Tenoretic is a fixed-dose combination of two active ingredients: atenolol and chlorthalidone. Atenolol is marketed under the brand name Tenormin, and chlorthalidone is marketed under the brand name Thalitone. Tenoretic is the combination product that delivers both medicines simultaneously.

Q: Does Tenoretic cause drowsiness or trouble sleeping?

A: Official safety documents list fatigue and drowsiness as known side effects of the medication. The possibility of insomnia (trouble sleeping) has also been reported in clinical experience with the drug.

Q: Is there a recommended time of day to take Tenoretic?

A: While the medicine is prescribed to be taken once daily, the diuretic component increases the need to urinate. Due to the diuretic component, the medication is often prescribed for administration in the morning to reduce the risk of needing to urinate frequently during the night.

How should Tenoretic be stored and disposed of?

How to Store and Dispose of Tenoretic

Official regulatory documents define specific, mandatory conditions for storing and disposing of Tenoretic (atenolol and chlorthalidone) tablets to ensure product stability.


Storage Requirements

  • Temperature: Store at room temperature, typically defined as 15 C to 25 C (59 F to 77 F). Do not store above the stated limit, and protect from freezing.
  • Protection: The tablets must be kept in their original package to ensure protection from light and moisture.
  • Child Safety: Keep the medicine out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired Tenoretic must not be disposed of using standard household trash or wastewater (e.g., flushing down the toilet). Disposal must follow local pharmaceutical waste regulations, such as utilizing a drug take-back program or official collection points.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tenoretic found in:

A-Z Index: